Ann: Enrolment Completed in 1st Cohort of Cynata Clinical Trial, page-79

The problem is Truss, Ross has been saying the exact same thing for the last 3 years, talking up the "multiple shots on goal " strategy, talking up multiple licensee partners paying for the commercilisation of Cymerus etc etc. The fact is we have one potential licensee with an option, (albeit a big one in Fuji), and only half a Ph 1 trial completed in 3 years.
Talk about over promise and under deliver !
Perhaps some of the long term shareholders are justified in feeling more than a little peeved !
And given they bought in at 30 -35c level , it's understandable there's been a constant drip of selling capping the sp. as some feel justified at this level to take their profits and move on to other prospects.
The science and the tech behind this may be absolutely brilliant and world class, but if management are so complacent and so slow to deliver , there's going to be a constant revolving door of investors coming and going and a sp in limbo until something meaningful is delivered . At this rate, that may be quite some time given their track record.